Clinical Trial Update: Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab [Phase 2]

View source ↗

Summary

Phase 2 study evaluating disease risk mutation-guided finite acalabrutinib plus venetoclax for relapsed chronic lymphocytic leukemia and small lymphocytic lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Venetoclax (venetoclax)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: NOT_YET_RECRUITING